CompletedPhase 4

THE EFFECT OF NEBULIZED AZITHROMYCIN AS THERAPY FOR BRONCHOPULMONARY DYSPLASIA

Egypt100 participantsStarted 2024-10-02

Plain-language summary

The aim of the study is to determine the effectiveness of nebulized azithromycin therapy in prevention of BPD in very low birth weight preterm infants when compared with placebo.

Who can participate

Age range7 Days – 28 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Gestational age less than 32 weeks and birth weight less than 1500 g.
✓. Infants who are still in need of respiratory support at day 7 of life (intubated, or by non-invasive mechanical ventilation, including CPAP and high-flow nasal cannula, or any form of oxygen therapy).

What they're measuring

Development of BPD (bronchopulmonary dysplasia)

Timeframe: 28 days of life and/or 36 weeks postmenstrual age

Lung Ultrasound assessment

Timeframe: 14 days postnatal age.

Trial details

NCT IDNCT06584474

SponsorAlexandria University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-02

View on ClinicalTrials.gov More Bronchopulmonary Dysplasia trials